A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent anti-tumor response
The type 1 NKT cell stimulating glycolipid α-galactosylceramide (α-GalCer) was first identified by the Pharmaceutical Research Laboratory of Kirin Brewery in a screen for novel anti-tumor agents. Based on promising preclinical data it was tested as an anticancer drug in multiple clinical studies.
An Unexpected Moonlighting: Glycolytic Enzyme Aldolase B Acts as a Metabolic Switch for Metabolic Reprogramming in Hepatocellular Carcinogenesis
Using CRISPR based screening, we discovered that activation of the integrated stress response pathway enhances PD-L1 translation and promotes immune suppression in lung cancer.
Personalized OncoGenomics: A collaboration of scientific and clinical minds at BC Cancer is answering complex questions about cancer and its treatment